Abbisko Cayman's (HKG:2256) unit, Abbisko Therapeutics, reported "positive top-line results" for its Phase 3 MANEUVER study of pimicotinib after the study met primary endpoint with a response rate of 54% at week 25 compared with 3.2% for placebo, according to a Tuesday filing with the Hong Kong bourse.
Pimicotinib, a small molecule inhibitor of CSF-1R, has shown positive results in patients with tenosynovial giant cell tumor, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。